FDA slows down on drug reviews, approvals amid Trump admin chaos
FDA drug approvals slowed, review delays and rejections increased, manufacturing inspection issues rose, and a government shutdown prevents accepting new drug submissions.
Can AI companies turn brainrot into revenue? | TechCrunch
Startups face existential risk from the U.S. government shutdown due to delayed permits, visas, or regulatory approvals, while AI companies struggle with sustainable business models.